Eye Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.
| Status: | Completed |
|---|---|
| Conditions: | Ocular, Psychiatric |
| Therapuetic Areas: | Ophthalmology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/8/2014 |
| Start Date: | June 2013 |
| End Date: | June 2014 |
| Contact: | Jessica Jordan |
| Email: | research@midatlanticretina.com |
| Phone: | 215-928-3092 |
A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy
The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin)
on the rates of recurrent retinal detachment and scar tissue formation.
on the rates of recurrent retinal detachment and scar tissue formation.
Inclusion Criteria:
- Ability to provide written informed consent and comply with study assessments for the
full duration of the study
- Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD
due to PVR with planned silicone oil instillation.
Exclusion Criteria:
- Prior anti-VEGF (vascular endothelial growth factor) injections within 3 months of
retinal detachment surgery.
- Traction retinal detachment due to proliferative diabetic retinopathy.
- Inability to flatten retina completely intraoperatively
- Known allergy or contraindication to intravitreal bevacizumab
We found this trial at
1
site
Click here to add this to my saved trials
